2-piperidin-1-ylmethyl-indan-1-one | 4756-86-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-piperidin-1-ylmethyl-indan-1-one
• 英文别名: 2-Piperidinomethyl-indan-1-on；2-Piperidinomethyl-indanon-1；2-(Piperidino)methyl-1-indanone；2-(piperidin-1-ylmethyl)-2,3-dihydroinden-1-one
• CAS: 4756-86-9
• 化学式: C₁₅H₁₉NO
• 分子量: 229.322
• InChiKey: SQIWVUIDKFUELN-UHFFFAOYSA-N

物化性质

• 沸点：
  354.6±11.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl magnesium iodide 、 2-piperidin-1-ylmethyl-indan-1-one 在 乙醚 作用下， 生成 1-(3-ethyl-inden-2-ylmethyl)-piperidine
  参考文献：
  名称：

  N-取代基2-（氨基甲基）-茚满和茚满

  摘要：

  DOI：

  10.1002/hlca.194402701226
• 作为产物：
  描述：

  N-methylenepiperidinium chloride 、 1-茚酮 以 乙醇 、 苯 为溶剂， 反应 10.0h， 生成 2-piperidin-1-ylmethyl-indan-1-one
  参考文献：
  名称：

  Hypolipidemic effects of α, β, and γ-alkylaminophenone analogs in rodents

  摘要：

  A number of N-substituted beta-alkylaminophenone derivatives including two alpha- and two gamma-alkylaminophenone analogs were synthesized and investigated for hypolipidemic activity in mice at 8 mg/kg/day ip. Most of these analogs were found to be significantly more active than lovastatin and clofibrate. N-Phenylpiperazinopropiophenone 16 was one of the best derivatives, lowering serum cholesterol levels 41% and serum triglyceride levels 48% after 16 days of drug administration in CF1 mice. In Sprague-Dawley rats, N-phenylpiperazinopropiophenone at 8 mg/kg/day orally also demonstrated more potent hypolipidemic activity than clofibrate, gemfibrozil, and lovastatin at their therapeutic dosage. It significantly reduced tissue cholesterol and triglyceride levels in the aorta wall tissue and lowered the cholesterol and triglyceride levels in chylomicron, very low density lipid (VLDL) and low density lipid (LDL) fractions, while it significantly elevated the cholesterol levels in high density lipid (HDL) fraction. This compound also proved to be active in lowering both cholesterol and triglyceride levels in hyperlipidemic mice and rats induced with atherogenic diet. In vitro liver acetyl coenzyme A (CoA) synthetase, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase, acyl CoA cholesterol acyl transferase (ACAT), sn-glycerol-3-phosphate acyltransferase, phosphatidylate phosphohydrolase, and hepatic lipoprotein lipase activities were significantly inhibited by N-phenylpiperazinopropiophenone from 25 to 100 mu M.

  DOI：

  10.1016/0223-5234(96)80365-5

文献信息

• Reaktionen von Cyclo-Alkanon-Mannich-Basen mit Diazoalkanen: Synthese potentieller Antikonvulsiva und Lokalanästhetika
  作者：Hermann J. Roth、Gerd Wolf

  DOI：10.1002/ardp.19803130706

  日期：——

  Reaktion von Diazomethan bzw. Diazoethan mit Cycloalkanon‐ oder Benzocycloalkanon‐Mannich‐Basen entstehen unterschiedliche Produkte. Bei Einsatz der Mannichbase 1 erhält man statt der erwarteten Spiro‐Epoxide bzw. Oxirane einen α,β‐ungesättigten Alkohol 4, bei Verwendung der Benzocycloalkanon‐Mannich‐Basen 5, 6, 7 und 14 enantiomere bzw. diastereomere Spiro‐Δ1‐oder/und ‐Δ2‐Pyrazoline. 9 und 11 zeigen

  重氮甲烷或重氮乙烷与环烷酮或苯并环烷酮曼尼希碱的反应产生不同的产物。当使用曼尼希碱 1 时，得到 α, β-不饱和醇 4，而不是预期的螺 - 环氧化物或环氧乙烷；当使用苯并环烷酮曼尼希碱 5、6、7 和 14 时，对映体或非对映体螺 - Δ1 - 或 / 和 - Δ2-吡唑啉。图9和11显示了明显的抗惊厥作用。
• [EN] PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF<br/>[FR] PROCEDE DE PREPARATION DE DONEPEZIL ET DE SES DERIVES
  申请人：RANBAXY LAB LTD

  公开号：WO2004082685A1

  公开（公告）日：2004-09-30

  The invention relates to processes for the preparation of piperidylmethyl-indanones, and to the use of these compounds as intermediates for the preparation of benzyl-piperidylmethyl-indanones which are active compounds for the treatment of CNS disorders. The invention also relates to a process for the preparation of donepezil or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions that include the donepezil or a pharmaceutically acceptable salt thereof.

  本发明涉及制备哌啶甲基-茚烷酮的方法，以及使用这些化合物作为中间体制备苯甲基-哌啶甲基-茚烷酮，后者是治疗中枢神经系统疾病的活性化合物。本发明还涉及制备多奈哌齐或其药学上可接受的盐的方法，以及包括多奈哌齐或其药学上可接受的盐的制药组合物。
• Stable lamotrigine pharmaceutical compositions and processes for their preparation
  申请人：Kumar Yatendra

  公开号：US20070129549A1

  公开（公告）日：2007-06-07

  The invention relates to processes for the preparation of piperidylmethyl-indanones, and to the use of these compounds as intermediates for the preparation of benzyl-piperidylmethyl-indanones which are active compounds for the treatment of CNS disorders. The invention also relates to a process for the preparation of donepezil or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions that include the donepezil or a pharmaceutically acceptable salt thereof.

  本发明涉及制备哌啶基甲基-茚酮类化合物的方法，以及将这些化合物用作制备苯基-哌啶基甲基-茚酮类活性化合物（用于治疗中枢神经系统疾病）的中间体的用途。本发明还涉及制备多奈哌齐或其药学上可接受的盐的方法，以及包括多奈哌齐或其药学上可接受的盐的制药组合物。
• 2-amino-methyl-indenes and their production
  申请人：CIBA PHARM PROD INC

  公开号：US02441069A1

  公开（公告）日：1948-05-04
• PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF
  申请人：RANBAXY LABORATORIES, LTD.

  公开号：EP1608371A1

  公开（公告）日：2005-12-28